Stanislav Ignatenko

971 total citations
19 papers, 463 citations indexed

About

Stanislav Ignatenko is a scholar working on Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Stanislav Ignatenko has authored 19 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Genetics and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Stanislav Ignatenko's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Pharmaceutical studies and practices (3 papers) and Mesenchymal stem cell research (2 papers). Stanislav Ignatenko is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Pharmaceutical studies and practices (3 papers) and Mesenchymal stem cell research (2 papers). Stanislav Ignatenko collaborates with scholars based in Germany, United States and Switzerland. Stanislav Ignatenko's co-authors include Frank Wagner, Patrik Maurer, Martin F. Bachmann, H Stocker, Thomas D. Pfister, Philipp Müller, Alain C. Tissot, Robert Sabat, Hans‐Dieter Volk and Juerg Nussberger and has published in prestigious journals such as The Lancet, Diabetes and Annals of the Rheumatic Diseases.

In The Last Decade

Stanislav Ignatenko

19 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanislav Ignatenko Germany 9 150 122 87 77 67 19 463
Yuemiao Zhang China 15 96 0.6× 106 0.9× 64 0.7× 54 0.7× 59 0.9× 46 555
Marie‐Anne Valentin Switzerland 7 239 1.6× 115 0.9× 81 0.9× 62 0.8× 51 0.8× 13 662
Heleia Roca-Ho Spain 12 98 0.7× 158 1.3× 77 0.9× 92 1.2× 48 0.7× 21 648
Yasuhito Suzuki Japan 13 89 0.6× 155 1.3× 47 0.5× 71 0.9× 47 0.7× 46 627
Nithya Krishnan United States 16 124 0.8× 232 1.9× 66 0.8× 40 0.5× 149 2.2× 43 695
Xinmiao Wang China 10 108 0.7× 204 1.7× 50 0.6× 28 0.4× 45 0.7× 25 496
Toru Sawada Japan 13 116 0.8× 98 0.8× 46 0.5× 108 1.4× 121 1.8× 46 553
Min‐Tao Gai China 13 62 0.4× 111 0.9× 96 1.1× 55 0.7× 94 1.4× 43 417
Bilgehan Karadağ Türkiye 17 89 0.6× 263 2.2× 246 2.8× 23 0.3× 124 1.9× 68 780
Masaya Tsuda Japan 14 52 0.3× 167 1.4× 103 1.2× 17 0.2× 103 1.5× 32 425

Countries citing papers authored by Stanislav Ignatenko

Since Specialization
Citations

This map shows the geographic impact of Stanislav Ignatenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanislav Ignatenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanislav Ignatenko more than expected).

Fields of papers citing papers by Stanislav Ignatenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanislav Ignatenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanislav Ignatenko. The network helps show where Stanislav Ignatenko may publish in the future.

Co-authorship network of co-authors of Stanislav Ignatenko

This figure shows the co-authorship network connecting the top 25 collaborators of Stanislav Ignatenko. A scholar is included among the top collaborators of Stanislav Ignatenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanislav Ignatenko. Stanislav Ignatenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Haahr, Hanne, Janne R. Hingst, Shan Jiang, et al.. (2024). The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec. Clinical Pharmacokinetics. 63(6). 819–830. 7 indexed citations
3.
Baribaud, Frédéric, Stanislav Ignatenko, Lina Zhu, et al.. (2024). POS0551 PHARMACODYNAMIC EFFECTS AND EXPLORATORY EFFICACY OF AFIMETORAN, A TLR7/8 INHIBITOR, IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 83. 1110–1111. 2 indexed citations
4.
Klughammer, Barbara, Luca Piali, S. Nagel, et al.. (2023). P805 Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative Colitis. Journal of Crohn s and Colitis. 17(Supplement_1). i938–i938. 4 indexed citations
5.
Klughammer, Barbara, Luca Piali, Christoph Jochum, et al.. (2023). A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clinical and Translational Medicine. 13(11). e1471–e1471. 33 indexed citations
6.
Ignatenko, Stanislav, et al.. (2023). 808-P: Pharmacokinetic Properties of Once-Weekly Insulin Icodec in Individuals with Renal Impairment vs. Normal Renal Function. Diabetes. 72(Supplement_1). 1 indexed citations
7.
Tan, Susanne, Stanislav Ignatenko, Frank Wagner, et al.. (2021). Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial. Diabetes Obesity and Metabolism. 23(11). 2595–2599. 41 indexed citations
8.
Tan, Susanne, Stanislav Ignatenko, Frank Wagner, et al.. (2021). Licogliflozin <i>versus</i> Placebo in Women with Polycystic Ovary Syndrome (PCOS): A Randomised, Double-Blind, Phase 2 Trial. SSRN Electronic Journal. 1 indexed citations
9.
Vaidya, Soniya, Brian Ethell, Anton Drollmann, et al.. (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 64. 101964–101964. 9 indexed citations
10.
Tillmann, Hanns-Christian, Brian Ethell, Anton Drollmann, et al.. (2019). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects. PA2540–PA2540. 1 indexed citations
11.
12.
Lü, Peng, Roy Fleischmann, C. Martin Curtis, et al.. (2017). Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 27(2). 290–302. 21 indexed citations
13.
Ignatenko, Stanislav, Birte K. Skrumsager, & Ulrik Mouritzen. (2016). Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial. International Journal of Clinical Pharmacology and Therapeutics. 54(4). 243–252. 39 indexed citations
14.
Космачева, С. М., et al.. (2015). The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus. Bulletin of Experimental Biology and Medicine. 159(4). 576–581. 32 indexed citations
15.
Космачева, С. М., et al.. (2014). Effect of Platelet Releasate on Osteogenic Differentiation of Human Mesenchymal Bone Marrow Stem Cells. Bulletin of Experimental Biology and Medicine. 156(4). 560–565. 7 indexed citations
16.
17.
Tissot, Alain C., Patrik Maurer, Juerg Nussberger, et al.. (2008). Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. The Lancet. 371(9615). 821–827. 208 indexed citations
18.
Potapov, Evgenij, Stanislav Ignatenko, Boris Nasseri, et al.. (2004). Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support. The Annals of Thoracic Surgery. 77(3). 869–874. 24 indexed citations
19.
Potapov, Evgenij, et al.. (2003). CLINICAL SIGNIFICANCE OF PIA POLYMORPHISM OF PLATELET GP IIb/IIIa RECEPTORS DURING LONG-TERM VAD SUPPORT. ASAIO Journal. 49(2). 145–145. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuemiao Zhang Breakdown of academic impact, for papers by Marie‐Anne Valentin Breakdown of academic impact, for papers by Heleia Roca-Ho Breakdown of academic impact, for papers by Yasuhito Suzuki Breakdown of academic impact, for papers by Nithya Krishnan Breakdown of academic impact, for papers by Xinmiao Wang Breakdown of academic impact, for papers by Toru Sawada Breakdown of academic impact, for papers by Min‐Tao Gai Breakdown of academic impact, for papers by Bilgehan Karadağ Breakdown of academic impact, for papers by Masaya Tsuda
Rankless by CCL
2026